Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[1‑13C] sodium acetate is a stable isotope-labeled form of sodium acetate in which the carbon at position 1 of the acetyl group is replaced with the non-radioactive isotope carbon‑13. It is chemically identical to regular sodium acetate except for this isotopic substitution. The compound is primarily used as a tracer in metabolic studies and diagnostic imaging, such as hyperpolarized MRI/MRS and metabolomics research. In these applications, it allows for tracking of metabolic pathways involving the acetyl group due to its unique NMR signature. Mechanistically, after administration, [1‑13C] sodium acetate enters cellular metabolism where it can be converted into acetyl-CoA and further metabolized via the tricarboxylic acid cycle or other biosynthetic pathways; its labeled carbon enables precise study of these processes[2][3]. It does not have direct pharmacological activity but serves as an investigative tool in clinical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [1-13C] sodium acetate.